694. Deputy Matt Shanahan asked the Minister for Health the downstream and overall cost-benefit analysis conducted by the corporate pharmaceutical unit when assessing reimbursement applications for novel and generic drug applications; his views on whether the full system savings are being considered in such applications; if evidence of same in action can be demonstrated; and if he will make a statement on the matter. [39906/20]

Summary

694. Deputy Matt Shanahan asked the Minister for Health the downstream and overall cost-benefit analysis conducted by the corporate pharmaceutical unit when assessing reimbursement applications for novel and generic drug applications; his views on whether the full system savings are being considered in such applications; if evidence of same in action can be demonstrated; and if he will make a statement on the matter. [39906/20]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 1 December 2020

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.